Targeted delivery of Dicer-substrate siRNAs using a dual targeting peptide decorated dendrimer delivery system

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 8, 2014, Pages 1627-1636

  Liu, Xiaoxuan ^a   Liu, Cheng ^a,b   Chen, Chao ^a,c   Bentobji, Mélanie ^d   Cheillan, Francine Azario ^d   Piana, Jeanne Thomassin ^d   Qu, Fanqi ^b   Rocchi, Palma ^c,d,e,f   Peng, Ling ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b WUHAN UNIVERSITY   (China)

^c AIX MARSEILLE UNIVERSITY   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f CNRS   (France)

Author keywords

Dendrimer; Nanovector; Prostate cancer; SiRNA; Targeted delivery

Indexed keywords

DENDRIMERS; DISEASES; PEPTIDES; TRIETHANOLAMINE;

NANOVECTOR; POLYAMIDOAMINE DENDRIMERS; PROSTATE CANCERS; SIRNA; SMALL INTERFERING RNA (SIRNA); SYNTHETIC MACROMOLECULES; TARGETED DELIVERY; THERAPEUTIC PROPERTIES;

FUNCTIONAL POLYMERS;

ANTINEOPLASTIC AGENT; DENDRIMER; DICER; DICER SUBSTRATE SMALL INTERFERING RNA TRIETHANOLAMINE POLYAMIDOAMINE; DICER SUBSTRATE SMALL INTERFERING RNA TRIETHANOLAMINE POLYAMIDOAMINE POLYGLUTAMIC ACID POLYGLYCINE ARGINYLGLYCYLASPARTYLCYSTEINYLLYSINE; DOCETAXEL; HEAT SHOCK PROTEIN 27; INTEGRIN; NANOCARRIER; NEUROPILIN 1; PEPTIDE; POLYAMIDOAMINE; POLYGLUTAMIC ACID POLYGLYCINE ARGINYLGLYCYLASPARTYLCYSTEINYLLYSINE; SMALL INTERFERING RNA; TRIETHANOLAMINE; UNCLASSIFIED DRUG; DEAD BOX PROTEIN; DICER1 PROTEIN, HUMAN; RIBONUCLEASE III;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG UPTAKE; GENE SILENCING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; RNA INTERFERENCE; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; CONFOCAL MICROSCOPY; FLOW CYTOMETRY; GENE VECTOR; GENETICS; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEAD-BOX RNA HELICASES; DENDRIMERS; FLOW CYTOMETRY; GENE SILENCING; GENETIC VECTORS; HUMANS; MICROSCOPY, CONFOCAL; PEPTIDES; RIBONUCLEASE III; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84908576204     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2014.05.008     Document Type: Article

References (50)

1. Bourzac K. Nanotechnology: carrying drugs. Nature 2012, 491:S58-S60.
2. Lee C.C., MacKay J.A., Frechet J.M., Szoka F.C. Designing dendrimers for biological applications. Nat Biotechnol 2005, 23:1517-1526.
3. Mintzer M.A., Grinstaff M.W. Biomedical applications of dendrimers: a tutorial. Chem Soc Rev 2011, 40:173-190.
4. Liu X., Rocchi P., Peng L. Dendrimers as non-viral vectors for siRNA delivery. New J Chem 2012, 36:256-263.
5. Mehrabadi F.S., Fischer W., Haag R. Dendritic and lipid-based carriers for gene/siRNA delivery (a review). Curr Opin Solid State Mater Sci 2012, 16:310-322.
6. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
7. Hannon G.J. RNA interference. Nature 2002, 418:244-251.
8. Lee Y.S., Nakahara K., Pham J.W., Kim K., He Z., Sontheimer E.J., et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004, 117:69-81.
9. Pham J.W., Pellino J.L., Lee Y.S., Carthew R.W., Sontheimer E.J. A Dicer-2-dependent 80S complex cleaves targeted mRNAs during RNAi in Drosophila. Cell 2004, 117:83-94.
10. Tomari Y., Matranga C., Haley B., Martinez N., Zamore P.D. A protein sensor for siRNA asymmetry. Science 2004, 306:1377-1380.
11. Kim D.H., Behlke M.A., Rose S.D., Chang M.S., Choi S., Rossi J.J. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005, 23:222-226.
12. Kanasty R.L., Whitehead K.A., Vegas A.J., Anderson D.G. Action and reaction: the biological response to siRNA and its delivery vehicles. Mol Ther 2012, 20:513-524.
13. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
14. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
15. Liu X., Liu C., Catapano C.V., Peng L., Zhou J., Rocchi P. Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics. Biotechnol Adv 2014, 32:844-852.
16. Zhou J., Wu J., Hafdi N., Behr J.P., Erbacher P., Peng L. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun 2006, 2362-2364.
17. Liu X.X., Rocchi P., Qu F.Q., Zheng S.Q., Liang Z.C., Gleave M., et al. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells. ChemMedChem 2009, 4:1302-1310.
18. Zhou J., Neff C.P., Liu X., Zhang J., Li H., Smith D.D., et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol Ther 2011, 19:2228-2238.
19. Liu X., Liu C., Laurini E., Posocco P., Pricl S., Qu F., et al. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer. Mol Pharm 2012, 9:470-481.
20. Lang M.F., Yang S., Zhao C., Sun G., Murai K., Wu X., et al. Genome-wide profiling identified a set of miRNAs that are differentially expressed in glioblastoma stem cells and normal neural stem cells. PLoS One 2012, 7:e36248.
21. Posocco P., Liu X., Laurini E., Marson D., Chen C., Liu C., et al. Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencing. Mol Pharm 2013, 10:3262-3273.
22. Reebye V., Saetrom P., Mintz P.J., Huang K.W., Swiderski P., Peng L., et al. Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo. Hepatology 2014, 59:216-227.
23. Liu X., Wu J., Yammine M., Zhou J., Posocco P., Viel S., et al. Structurally flexible triethanolamine core PAMAM dendrimers are effective nanovectors for DNA transfection in vitro and in vivo to the mouse thymus. Bioconjug Chem 2011, 22:2461-2473.
24. Danhier F., Le Breton A., Preat V. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol Pharm 2012, 9:2961-2973.
25. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010, 10:9-22.
26. Marelli U.K., Rechenmacher F., Sobahi T.R., Mas-Moruno C., Kessler H. Tumor targeting via integrin ligands. Front Oncol 2013, 3:222.
27. Sugahara K.N., Teesalu T., Karmali P.P., Kotamraju V.R., Agemy L., Girard O.M., et al. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 2009, 16:510-520.
28. Teesalu T., Sugahara K.N., Kotamraju V.R., Ruoslahti E. C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc Natl Acad Sci U S A 2009, 106:16157-16162.
29. Zhou J., Liu J., Cheng C.J., Patel T.R., Weller C.E., Piepmeier J.M., et al. Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery. Nat Mater 2012, 11:82-90.
30. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
31. Fusi A., Procopio G., Della Torre S., Ricotta R., Bianchini G., Salvioni R., et al. Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori 2004, 90:535-546.
32. Stavridi F., Karapanagiotou E.M., Syrigos K.N. Targeted therapeutic approaches for hormone-refractory prostate cancer. Cancer Treat Rev 2010, 36:122-130.
33. Cornford P.A., Dodson A.R., Parsons K.F., Desmond A.D., Woolfenden A., Fordham M., et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res 2000, 60:7099-7105.
34. Rocchi P., So A., Kojima S., Signaevsky M., Beraldi E., Fazli L., et al. Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res 2004, 64:6595-6602.
35. Rocchi P., Jugpal P., So A., Sinneman S., Ettinger S., Fazli L., et al. Small interference RNA targeting heat-shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase-3 activation in vitro. BJU Int 2006, 98:1082-1089.
36. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23.
37. Acunzo J., Katsogiannou M., Rocchi P. Small heat shock proteins HSP27 (HspB1), alphaB-crystallin (HspB5) and HSP22 (HspB8) as regulators of cell death. Int J Biochem Cell Biol 2012, 44:1622-1631.
38. Arrigo A.P., Simon S., Gibert B., Kretz-Remy C., Nivon M., Czekalla A., et al. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett 2007, 581:3665-3674.
39. Ischia J., So A.I. The role of heat shock proteins in bladder cancer. Nat Rev Urol 2013, 10:386-395.
40. Hessenkemper W., Baniahmad A. Targeting heat shock proteins in prostate cancer. Curr Med Chem 2013, 20:2731-2740.
41. Jego G., Hazoume A., Seigneuric R., Garrido C. Targeting heat shock proteins in cancer. Cancer Lett 2013, 332:275-285.
42. Acunzo J., Andrieu C., Baylot V., So A., Rocchi P. Hsp27 as a therapeutic target in cancers. Curr Drug Targets 2014, 15:423-431.
43. Kamada M., So A., Muramaki M., Rocchi P., Beraldi E., Gleave M. Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 2007, 6:299-308.
44. Hotte S.J., Yu E.Y., Hirte H.W., Higano C.S., Gleave M.E., Chi K.N. OGX-427, a 20 methoxyethyl antisense oligonucleotide (ASO), against Hsp27: results of a first-in-human trial. J Clin Oncol 2009, 27. [Suppl; abstr 3506].
45. Hotte S.J., Yu E.Y., Hirte H.W., Higano C.S., Gleave M.E., Chi K.N. Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): final results. J Clin Oncol 2010, 28:3077.
46. Chi K.N., Hotte S.J., Ellard S., Gingerich J.R., Joshua A.M., Yu EYG M.E. A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). J Clin Oncol 2012, 30. [Suppl; abstr 4514].
47. Chi K.N., Sweeney C., Jacobs C., Stewart P.S., Hahn N.M. The Pacific trial: a randomized phase II study of OGX-427 in men with metastatic castration-resistant prostate cancer (mCRPC) and PSA progression while receiving abiraterone acetate (AA). J Clin Oncol 2013, 31. [Suppl; abstr TPS5101].
48. http://www.oncogenex.com/apatorsen-ogx-427.
49. Wu J., Zhou J., Qu F., Bao P., Zhang Y., Peng L. Polycationic dendrimers interact with RNA molecules: polyamine dendrimers inhibit the catalytic activity of Candida ribozymes. Chem Commun 2005, 313-315.
50. Shen X.C., Zhou J., Liu X., Wu J., Qu F., Zhang Z.L., et al. Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes. Org Biomol Chem 2007, 5:3674-3681.